Yelin Lapidot Holdings Management Ltd. raised its holdings in MediWound Ltd. (NASDAQ:MDWD - Free Report) by 13.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 851,361 shares of the biopharmaceutical company's stock after purchasing an additional 100,618 shares during the period. MediWound accounts for approximately 2.6% of Yelin Lapidot Holdings Management Ltd.'s portfolio, making the stock its 12th largest holding. Yelin Lapidot Holdings Management Ltd. owned approximately 7.89% of MediWound worth $15,154,000 as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. Investor AB purchased a new position in MediWound in the 3rd quarter valued at about $15,750,000. Rosalind Advisors Inc. lifted its stake in shares of MediWound by 22.3% during the third quarter. Rosalind Advisors Inc. now owns 628,050 shares of the biopharmaceutical company's stock valued at $11,343,000 after buying an additional 114,560 shares during the period. Sargent Investment Group LLC lifted its stake in shares of MediWound by 3.4% during the fourth quarter. Sargent Investment Group LLC now owns 121,190 shares of the biopharmaceutical company's stock valued at $2,217,000 after buying an additional 3,998 shares during the period. ARK Investment Management LLC purchased a new stake in MediWound in the 3rd quarter worth approximately $1,806,000. Finally, Silverberg Bernstein Capital Management LLC grew its stake in MediWound by 8.5% in the 4th quarter. Silverberg Bernstein Capital Management LLC now owns 91,884 shares of the biopharmaceutical company's stock worth $1,636,000 after acquiring an additional 7,200 shares during the period. 46.83% of the stock is currently owned by institutional investors and hedge funds.
MediWound Stock Performance
MediWound stock traded down $0.69 during midday trading on Tuesday, reaching $16.32. The stock had a trading volume of 59,756 shares, compared to its average volume of 91,778. The stock has a market capitalization of $176.03 million, a PE ratio of -5.63 and a beta of 0.81. The stock's 50-day simple moving average is $18.16 and its 200 day simple moving average is $17.70. MediWound Ltd. has a twelve month low of $12.78 and a twelve month high of $24.00.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on the company. HC Wainwright restated a "buy" rating and set a $25.00 price objective on shares of MediWound in a report on Friday, January 10th. Craig Hallum initiated coverage on shares of MediWound in a research report on Friday. They issued a "buy" rating and a $39.00 target price on the stock.
Get Our Latest Research Report on MediWound
MediWound Profile
(
Free Report)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
See Also
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
